Invea Therapeutics, Inc.
Guilford, US · Founded 2021 · Delaware corporation · 7 employees on LinkedIn · 1 known investors
Find your way into Invea Therapeutics, Inc.
591 people in our graph share verified history with the Invea Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Krishnan Nandabalan · together at Yale University (overlapped)
×3knows the team · via Yale University
×3knows the team · via Merck Sharp & Dohme
×3knows the team · via The National Institutes of Health
×2knows the team · via University of Kentucky
Invea Therapeutics is a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs), using artificial intelligence and machine learning to study inflammation mechanisms such as mast cell and inflammasome biology. It targets both common and rare IMIDs to serve patients with chronic inflammatory conditions.
Founders & leadership
Invea Therapeutics, Inc. was founded in 2021 by Krishnan Nandabalan.
KN
Krishnan NandabalaninFounder, Chairman, President, CEOKrishnan Nandabalan holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science and completed postdoctoral work at Yale University. He has over two decades of experience in pharmaceutical and biotechnology R&D, business development, and M&A, including roles as VP of Corporate Development at Genaissance Pharmaceuticals and Group Leader of Functional Genomics at CuraGen Corp, and co-founded BioXcel Corporation before leading its biotechnology spinout.
SA
Salvatore AlesciinChief Scientific OfficerSalvatore Alesci is a physician-scientist with 25+ years of experience in translational research, experimental medicine, and early clinical development across startup, biopharma, government, and non-profit organizations. His expertise spans immune-mediated inflammatory diseases, small molecules, biologics, and AI-enabled drug discovery, and he has published over 60 peer-reviewed articles.
AK
Aman KantinCo-founder and PresidentAman Kant is Chief Operating Officer of Invea Therapeutics, a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases using AI and machine learning. He has spent nearly two decades in biotechnology and artificial intelligence, co-founding two companies focused on AI-enabled drug discovery and leading corporate strategy, operations, financing, portfolio development, and clinical execution.
MJ
Michael J. AielloinChief Financial Officerformer
""
"Shunichiro ""Steve""" OkadaNamed on SEC filing
SL
Sandeep LaumasNamed on SEC filing
VM
Vimal MehtaNamed on SEC filing
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 3 rounds · 2022–2025
▶$120.3KraisedDec 2025 · 1 investors · BiotechnologyRule 506(b)
▶$120.3KraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Demetrios KydonieusDirector
- Aman KantExecutive Officer
- Salvatore AlesciExecutive Officer
- Michael J. AielloExecutive Officer
- Jonathan ZalevskyDirector
- "Shunichiro ""Steve""" OkadaExecutive Officer
- Stephen DobersteinDirector
- Kerrie BradyDirector
- Krishnan NandabalanExecutive Officer, Director
- Offering amount
- $120.3K
- Amount sold
- $120.3K
- Minimum investment
- $10K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$300KraisedApr 2025 · 2 investors · BiotechnologyRule 506(b)
▶$300KraisedApr 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krishnan NandabalanExecutive Officer, Director
- Salvatore AlesciExecutive Officer
- Demetrios KydonieusDirector
- Kerrie BradyDirector
- Aman KantExecutive Officer
- Stephen DobersteinDirector
- Jonathan ZalevskyDirector
- "Shunichiro ""Steve""" OkadaExecutive Officer
- Michael J. AielloExecutive Officer
- Offering amount
- $600K
- Amount sold
- $300K
- Minimum investment
- $10K
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedApr 2022 · 4 investors · BiotechnologyRule 506(b)
▶$1.5MraisedApr 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Salvatore AlesciExecutive Officer
- Jonathan ZalevskyDirector
- "Shunichiro ""Steve""" OkadaExecutive Officer
- Aman KantExecutive Officer
- Sandeep LaumasDirector
- Demetrios KydonieusDirector
- Vimal MehtaDirector
- Michael AielloExecutive Officer
- Krishnan NandabalanExecutive Officer, Director, Promoter
- Kerrie BradyDirector
- Offering amount
- $5.8M
- Amount sold
- $1.5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Enveda Biosciences12 shared keywordsEnveda operates a drug-discovery platform that analyzes natural samples—primarily plant-derived molecules—using mass spectrometry, AI foundation models, and automated high-throughput labs to identify their chemical structures and therapeutic properties. The company maintains a searchable library of plant molecules to find new medicines and applies its technology toward human and planetary health challenges.
IQVIA12 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld11 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Invea Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Invea Therapeutics, Inc. do?
- Invea Therapeutics is a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs), using artificial intelligence and machine learning to study inflammation mechanisms such as mast cell and inflammasome biology. It targets both common and rare IMIDs to serve patients with chronic inflammatory conditions.
- Who founded Invea Therapeutics, Inc.?
- Invea Therapeutics, Inc. was founded by Krishnan Nandabalan in 2021.
- Who are Invea Therapeutics, Inc.'s investors?
- Invea Therapeutics, Inc.'s investors include Connecticut Innovations.
- How much funding has Invea Therapeutics, Inc. raised?
- Invea Therapeutics, Inc. has disclosed $1.9M raised across 3 rounds.
- Where is Invea Therapeutics, Inc. headquartered?
- Invea Therapeutics, Inc. is headquartered in Guilford, US.